Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
0.76
+0.03 (4.11%)
Market open: Aug 12, 2026, 12:21 PM EDT
0.73
0.00 (0.00%)
Previous after-hours: Aug 11, 2026, 7:34 PM EDT
Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary of Leonard-Meron Biosciences, Inc.
| Name | Position |
|---|---|
| Dr. Myron S. Czuczman M.D. | Executive VP & Chief Medical Officer |
| Mr. Jaime Bartushak | Chief Financial Officer & Treasurer |
| Mr. Leonard L. Mazur | CEO, President & Executive Chairman |
| Mr. Myron Z. Holubiak | Secretary & Executive Vice Chairman |
| Date | Type | Document |
|---|---|---|
| 2026-08-05 | 8-K | ea0300371-8k_citius.htm |
| 2026-06-01 | 8-K | ea0292903-8k_citius.htm |
| 2026-05-29 | S-3 | ea0291447-s3_citius.htm |
| 2026-05-29 | DEF 14C | ea0292248-def14c_citius.htm |
| 2026-05-19 | PRE 14C | ea0290807-pre14c_citius.htm |
| 2026-05-15 | 8-K | ea0291035-8k_citius.htm |
| 2026-05-15 | 10-Q | ea0290553-10q_citius.htm |
| 2026-05-06 | 8-K | ea0289297-8k_citius.htm |
| 2026-04-29 | 8-K | ea0288202-8k_citius.htm |
| 2026-04-28 | 8-K | ea0288020-8k_citius.htm |